LLVK is a selective IκB phosphorylation inhibitor. LLVK reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6 , TNF-α). LLVK is promising for research of inflammatory bowel disease and rheumatoid arthritis.
Products | Products > Peptides | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > NF-κB | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > IKK | Products > Signaling Pathways > NF-κB
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye